Log in to save to my catalogue

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cel...

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cel...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2718124803

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

About this item

Full title

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2022-10, Vol.23 (10), p.1274-1286

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundPembrolizumab is a standard-of-care for advanced non-small-cell lung cancer (NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage IB–IIIA NSCLC. MethodsIn this randomised, triple-blind, phase 3 trial (PEARLS/KEYNOTE-091), patients were recruited from 196 medical centres in 29 countries. Eligible patie...

Alternative Titles

Full title

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2718124803

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2718124803

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(22)00518-6

How to access this item